It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a […]

Nivolumab immunotherapy appeared safe and feasible to administer in conjunction with radiation and chemotherapy for patients with newly diagnosed local-regionally advanced squamous cell carcinoma of the […]

A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s […]

Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. Imfinzi is a […]

New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to new data from the European Society for Medical Oncology

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a way to rein in an overactive protein that drives some aggressive leukemias. The renegade molecule, MEF2C, […]

Cellular immunotherapies such as chimeric antigen receptor therapy are a promising approach for treatment of multiple myeloma. CAR T-cells have impressive activity against leukemia and lymphoma, […]